Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma
Abstract
1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Freeman, C.; Berg, J.W.; Cutler, S.J. Occurrence and prognosis of extranodal lymphoma. Cancer 1972, 29, 252–260. [Google Scholar] [CrossRef] [PubMed]
- Ferry, J.A.; Fung, C.Y.; Zukerberg, L.; Lucarelli, M.J.; Hasserjian, R.P.; Preffer, F.I.; Harris, N.L. Lymphoma of the ocular adnexa: A study of 353 cases. Am. J. Surg. Pathol. 2007, 31, 170–184. [Google Scholar] [CrossRef] [PubMed]
- Kaddu-Mulindwa, D.; Thurner, L.; Christofyllakis, K.; Bewarder, M.; Kos, I.A. Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. Cancers 2022, 14, 3019. [Google Scholar] [CrossRef] [PubMed]
- Ferreri, A.J.; Dolcetti, R.; Du, M.Q.; Doglioni, C.; Resti, A.G.; Politi, L.S.; De Conciliis, C.; Radford, J.; Bertoni, F.; Zucca, E.; et al. OAML: An intriguing model for antigen-driven lymphomagenesis and microbial targeted therapy. Ann. Oncol. 2008, 19, 835–846. [Google Scholar] [CrossRef] [PubMed]
- Johnson, J.G.; Terpak, L.A.; Margo, C.E.; Setoodeh, R. Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa. Cancer Control. 2016, 23, 140–149. [Google Scholar] [CrossRef] [PubMed]
- Peterson, K.; Gordon, K.B.; Heinemann, M.; DeAngelis, L.M. The clinical spectrum of ocular lymphoma. Cancer 1993, 72, 843–849. [Google Scholar] [CrossRef]
- Hormigo, A.; DeAngelis, L.M. Primary ocular lymphoma: Clinical features, diagnosis, and treatment. Clin. Lymphoma 2003, 4, 22–29. [Google Scholar] [CrossRef] [PubMed]
- NCCN Clinical Practice Guidelines in Oncology, EMZLMG-2, ver. 6.2023—10 October 2023. Available online: https://jnccn.org/view/journals/jnccn/21/11/article-p1118.xml (accessed on 19 October 2023).
- Uno, T.; Isobe, K.; Shikama, N.; Nishikawa, A.; Oguchi, M.; Ueno, N.; Itami, J.; Ohnishi, H.; Mikata, A.; Ito, H. Radiotherapy for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: A multi-institutional, retrospective review of 50 patients. Cancer 2003, 98, 865–871. [Google Scholar] [CrossRef] [PubMed]
- Woolf, D.K.; Kuhan, H.; Shoffren, O.; Akinnawo, E.M.; Sivagurunathan, B.; Boyce, H.; Plowman, P.N. Outcome of primary lymphoma of the ocular adnexal (orbital lymphoma) treated with radiotherapy. Clin. Oncol. R Coll. Radiol. 2015, 27, 153–159. [Google Scholar] [CrossRef]
- Hashimoto, N.; Sasaki, R.; Nishimura, H.; Yoshida, K.; Miyawaki, D.; Nakayama, M.; Uehara, K.; Okamoto, Y.; Ejima, Y.; Azumi, A.; et al. Long-term outcome and patterns of failure of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 1509–1514. [Google Scholar] [CrossRef]
- Kiesewetter, B.; Lukas, J.; Kuchar, A.; Mayerhoefer, M.E.; Streubel, B.; Lagler, H.; Müllauer, L.; Wöhrer, S.; Fischbach, J.; Raderer, M. Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: Single center experience of 60 patients. PLoS ONE 2014, 9, e104004. [Google Scholar] [CrossRef] [PubMed]
- Nuzzi, R.; Trossarello, M.; Bartoncini, S.; Marolo, P.; Franco, P.; Mantovani, C.; Ricardi, U. Ocular Complications After Radiation Therapy: An Observational Study. Clin. Ophthalmol. 2020, 14, 3153–3166. [Google Scholar] [CrossRef] [PubMed]
- Fasola, C.E.; Jones, J.; Huang, D.D.; Le, Q.-T.; Hoppe, R.T.; Donaldson, S.S. Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma. Int. J. Radiat. Oncol. 2013, 86, 930–935. [Google Scholar] [CrossRef] [PubMed]
- Tuncer, S.; Tanyıldız, B.; Basaran, M.; Buyukbabani, N.; Dogan, O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: Single institution experience. Curr. Eye Res. 2015, 40, 780–785. [Google Scholar] [CrossRef] [PubMed]
- Ferreri, A.J.; Ponzoni, M.; Martinelli, G.; Muti, G.; Guidoboni, M.; Dolcetti, R.; Doglioni, C. Rituximab in patients with mucosa-associated lymphoid tissue type lymphoma of the ocular adnexa. Haematologica 2005, 90, 1578–1579. [Google Scholar] [PubMed]
- Song, E.-K.; Kim, S.-Y.; Kim, T.M.; Lee, K.-W.; Yun, T.; Na, I.-I.; Shin, H.; Lee, S.H.; Kim, D.W.; Khwarg, S.I.; et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann. Oncol. 2008, 19, 242–246. [Google Scholar] [CrossRef] [PubMed]
- Ben Simon, G.J.; Cheung, N.; McKelvie, P.; Fox, R.; McNab, A.A. Oral chlorambucil for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006, 113, 1209–1213. [Google Scholar] [CrossRef] [PubMed]
- Decaudin, D.; de Cremoux, P.; Vincent-Salomon, A.; Dendale, R.; Rouic, L.L.-L. Ocular adnexal lymphoma: A review of clinicopathologic features and treatment options. Blood 2006, 108, 1451–1460. [Google Scholar] [CrossRef] [PubMed]
- Kang, H.J.; Kim, W.S.; Kim, S.J.; Lee, J.J.; Yang, D.H.; Kim, J.S.; Lee, S.R.; Lee, G.W.; Kim, H.J.; Kim, H.Y.; et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann. Hematol. 2012, 91, 543–551. [Google Scholar] [CrossRef]
- Aguiar-Bujanda, D.; Llorca-Mártinez, I.; Rivero-Vera, J.C.; Blanco-Sánchez, M.J.; Jiménez-Gallego, P.; Mori-De Santiago, M.; Limeres-Gonzalez, M.A.; Cabrera-Marrero, J.C.; Hernández-Sosa, M.; Galván-Ruíz, S.; et al. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone. Hematol. Oncol. 2014, 32, 139–144. [Google Scholar] [CrossRef]
- Oh, S.Y.; Kim, W.S.; Kim, J.S.; Kim, S.J.; Yoon, D.H.; Yang, D.H.; Lee, W.S.; Kim, H.J.; Yhim, H.Y.; Jeong, S.H.; et al. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for improving survival of lymphoma (CISL) study. Cancer Commun. 2019, 39, 58. [Google Scholar] [CrossRef]
- Flinn, I.W.; van der Jagt, R.; Kahl, B.S.; Wood, P.; Hawkins, T.E.; MacDonald, D.; Hertzberg, M.; Kwan, Y.-L.; Simpson, D.; Craig, M.; et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood 2014, 123, 2944–2952. [Google Scholar] [CrossRef]
- Cunningham, D.; Hawkes, E.A.; Jack, A.; Qian, W.; Smith, P.; Mouncey, P.; Pocock, C.; Ardeshna, K.M.; Radford, J.A.; McMillan, A.; et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013, 381, 1817–1826. [Google Scholar] [CrossRef]
- Zucca, E.; Arcaini, L.; Buske, C.; Johnson, P.W.; Ponzoni, M.; Raderer, M.; Ricardi, U.; Salar, A.; Stamatopoulos, K.; Thieblemont, C.; et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2020, 31, 17–29. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wen, Y.-C.; Huang, T.-C.; Tsai, W.-C.; Lai, S.-W. Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma. Medicina 2024, 60, 706. https://doi.org/10.3390/medicina60050706
Wen Y-C, Huang T-C, Tsai W-C, Lai S-W. Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma. Medicina. 2024; 60(5):706. https://doi.org/10.3390/medicina60050706
Chicago/Turabian StyleWen, Yao-Chang, Tzu-Chuan Huang, Wen-Chiuan Tsai, and Shiue-Wei Lai. 2024. "Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma" Medicina 60, no. 5: 706. https://doi.org/10.3390/medicina60050706
APA StyleWen, Y.-C., Huang, T.-C., Tsai, W.-C., & Lai, S.-W. (2024). Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma. Medicina, 60(5), 706. https://doi.org/10.3390/medicina60050706